SLC25A22

Across TCGA pan-cancer cohorts, SLC25A22 RNA differs between tumor and matched normal tissue in 18 of 18 cancer types tested, making tumor–normal expression one of SLC25A22’s most consistent transcriptional readouts.

The strongest signal is observed in colon adenocarcinoma (COAD), where SLC25A22 RNA is more highly expressed in tumor relative to normal tissue. In most cancer types SLC25A22 is over-expressed in tumor, although a few such as KICH show the opposite, repressed pattern.

COAD, HNSC, and STAD are the cancer types where SLC25A22 tumor–normal differential expression is most reproducible.

RNA tumor vs normal associations by lineage

Ranked by sampling consensus. Fold-change is the tumor-versus-normal difference in SLC25A22 RNA (log₂); positive values indicate higher expression in tumor. p-values are from the differential-expression test.

Lineage	Gender	Stage	Fold-change	p	Sampling consensus
COAD	Male	IV	+2.138	<.001	11	view →
HNSC	Male	All	+1.411	<.001	10	view →
STAD	Male	III,IV	+2.034	<.001	9	view →
BLCA	All	All	+1.105	<.001	9	view →
KIRP	Female	II,III,IV	+0.997	<.001	8	view →
LUAD	Female	III,IV	+1.196	<.001	7	view →
LUSC	Male	All	+0.743	<.001	7	view →
BRCA	All	III,IV	+1.178	<.001	6	view →
UCEC	All	All	+1.067	<.001	6	view →
ESCA	All	II,III,IV	+1.489	.002	4	view →
READ	All	All	+1.122	.001	3	view →
THCA	Female	II,III,IV	+0.358	.016	3	view →

Pink = over-expressed in tumor, green = repressed in tumor. Showing the 12 strongest of 18 lineages.

SLC25A22–COAD

Open the COAD breakdown →